Lanraplenib
GS-US-436-4092
Phase 2 small_molecule completed
Quick answer
Lanraplenib for Cutaneous Lupus Erythematosus is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lakefront Biotherapeutics NV
- Indication
- Cutaneous Lupus Erythematosus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed